Delcath Systems (NASDAQ:DCTH) Sets New 52-Week High – What’s Next?

Delcath Systems, Inc. (NASDAQ:DCTH)’s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $17.42 and last traded at $17.22, with a volume of 1228262 shares changing hands. The stock had previously closed at $16.67.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DCTH. HC Wainwright restated a “buy” rating and issued a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research report on Friday, August 7th. Wall Street Zen raised shares of Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Zacks Research raised shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a report on Monday. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research report on Friday, August 7th. Finally, BTIG Research increased their price objective on Delcath Systems from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and an average target price of $23.17.

Delcath Systems Price Performance

The firm has a market capitalization of $602.39 million, a P/E ratio of 1,737.74 and a beta of 0.52. The stock’s 50 day moving average is $12.88 and its two-hundred day moving average is $11.06.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The firm had revenue of $29.13 million for the quarter, compared to analysts’ expectations of $26.25 million. As a group, equities research analysts expect that Delcath Systems, Inc. will post -0.17 EPS for the current year.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently made changes to their positions in DCTH. Deutsche Bank AG lifted its stake in Delcath Systems by 5.4% in the fourth quarter. Deutsche Bank AG now owns 24,162 shares of the company’s stock valued at $244,000 after buying an additional 1,248 shares during the period. California State Teachers Retirement System acquired a new position in shares of Delcath Systems during the 2nd quarter worth about $26,000. Intech Investment Management LLC increased its stake in shares of Delcath Systems by 13.1% in the 4th quarter. Intech Investment Management LLC now owns 17,595 shares of the company’s stock valued at $178,000 after acquiring an additional 2,035 shares during the last quarter. AWM Investment Company Inc. increased its stake in shares of Delcath Systems by 3.9% in the 4th quarter. AWM Investment Company Inc. now owns 60,000 shares of the company’s stock valued at $606,000 after acquiring an additional 2,279 shares during the last quarter. Finally, Royal Bank of Canada raised its position in shares of Delcath Systems by 14.8% in the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after acquiring an additional 2,364 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.